Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Innovent Biologics (Suzhou) Co: Clinical Trials & FDA Approval Profile

Innovent Biologics (Suzhou) Co (Global / Institutional) sponsors 93 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 37 active protocols (17 recruiting now), 37 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)15.1%
Median Closed Enrollment vs National (145 pts)203 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Innovent Biologics (Suzhou) Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)93
Active Pipeline (Recruiting Now)37 (17)
Completed vs Stopped Early37 / 14 (15.1%)
Median Closed Actual Enrollment203 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Innovent Biologics (Suzhou) Co
Hospital Research SiteLocationShared Protocols
Peking University People's HospitalBeijing, Beijing Municipality7
Sun Yat-sen University Cancer CenterGuangzhou, Guangdong6
Beijing Cancer HospitalBeijing, Beijing Municipality6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Innovent Biologics (Suzhou) Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06081920A Study of IBI363 in Subjects With Advanced MelanomaPhase IIRECRUITING
NCT06238843A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CPhase IIIACTIVE NOT RECRUITING
NCT06797297A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced oPhase IIACTIVE NOT RECRUITING
NCT05607680A Study of IBI362 in Participants With Obesity or OverweightPhase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Innovent Biologics (Suzhou) Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI